Versant Capital Management, Inc
Position in INBX — Inhibrx Biosciences, Inc.
CIK 1735057
PHOENIX, AZ
Position in INBX
as of Jun 30, 2026
· filed Jul 2, 2026
Position Value
$15,918
+$4,624 QoQ
Shares Held
168
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#141
of 162 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INBX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Versant Capital Management, Inc holds $5,555,601 across 126 Biotechnology names. INBX ranks #58 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
2,357 | $567,966 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,055 | $524,050 | |
| 3 | ARGX |
Argenx SE
|
419 | $388,735 | |
| 4 | GMAB |
Genmab A/S
|
11,712 | $321,728 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
344 | $214,497 | |
| 6 | CELC |
Celcuity Inc.
|
1,630 | $170,530 | |
| 7 | MRNA |
Moderna, Inc.
|
2,189 | $153,295 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
2,549 | $145,853 |
All Filings in INBX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $15,918 | 168 | Shares | Sole | 2026-07-02 | |
| 2026-03-31 | $11,294 | 168 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $13,272 | 168 | Shares | Sole | 2026-01-08 | |
| 2025-09-30 | $5,658 | 168 | Shares | Sole | 2025-10-27 | |
| 2025-06-30 | $2,397 | 168 | Shares | Sole | 2025-07-07 | |
| 2025-03-31 | $5,540 | 396 | Shares | Sole | 2025-04-03 | |
| No filing history on record for this holder in this stock. | ||||||